- Prosensa Advances Three Exon Skipping Candidates for Duchenne Muscular Dystrophy into the Next Development Stage
- Brown licenses potential muscular dystrophy treatment to Tivorsan Pharmaceuticals
- Prosensa and GlaxoSmithKline Initiate Development of Four Additional Products under Existing Alliance in Duchenne Muscular Dystrophy
- Prosensa, GSK initiate additional programs for DMD
- AVI-4658 Oligomer Demonstrates Dose Response
Join us November 5, 2011 from 6:30pm - 11pm to help find the cure for Duchenne Muscular Dystrophy.
Buy tickets here.
Learn moreBuy tickets here.